Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Proton pump inhibitor use in clopidogrel-treated post-percutaneous coronary intervention patients was not associated with an increased risk of all-cause death, nonfatal myocardial infarction, repeat revascularization, or major adverse cardiovascular events.

Proton Pump Inhibitors and Clopidogrel